VivoSeq
Immunology

Antiphospholipid Syndrome

25

Pipeline Programs↗

5

Active Trials↗

15

Companies Involved↗

Antiphospholipid Syndrome is an emerging landscape with 25 programs across 15 companies. The most active players are Daiichi Sankyo, Bayer, Roche. 3 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

6/100

Mech. Concentration

15/100

Completion Rate

56/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Daiichi Sankyo logo

Daiichi Sankyo

1 program

Phase 1Bayer logo

Bayer

2 programs

Phase 1Roche logo

Roche

2 programs

Phase 2Novartis logo

Novartis

2 programs

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2B

BeOne Medicines

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

76%

Small molecule

19 of 25 classified programs — the dominant modality here.

24%ALL OTHERSMonoclonal antibody416%Protein / enzyme14%Cell therapy14%

Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 100% of 30 pipeline programs.

Analysis

Trial Status

26

clinical trials

Completed9 · 35%
Unknown status5 · 19%
Recruiting4 · 15%
Terminated4 · 15%
Withdrawn3 · 12%
Not yet recruiting1 · 4%

Clinical Trials

Trial Activity

26 trials

Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05199909·10 enrolled
Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome
Recruiting·—·N/A·NCT06373926·60 enrolled
Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE
Recruiting·SSeoul National University Hospital·Phase 4·NCT05995600·200 enrolled
Daratumumab in Primary Antiphospholipid Syndrome
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05671757·22 enrolled
The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study
Not yet recruiting·PPeking University People's Hospital·Phase 2·NCT06504420·70 enrolled
A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome
Completed·HHospital for Special Surgery, New York·Phase 2·NCT00537290·19 enrolled
Rivaroxaban for Patients With Antiphospholipid Syndrome
Completed·HHospital Universitari Vall d'Hebron Research Institute·Phase 3·NCT02926170·190 enrolled
Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
Completed·—·Phase 4·NCT02295475·48 enrolled
Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome
Completed·NNational and Kapodistrian University of Athens·N/A·NCT04153201·50 enrolled
Multi-organ Screening for Asymptomatic Ischaemia in Antiphospholipid Syndrome
Completed·—·N/A·NCT03348306·50 enrolled
Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome
Completed·UUniversity Hospital, Rouen·Phase 2·NCT02595346·25 enrolled
Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome
Completed·—·Phase 2·NCT01051778·60 enrolled
Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX)
Completed·GGroupe Hospitalier Pitie-Salpetriere·N/A·NCT03994302·2,700 enrolled
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
Completed·HHospital for Special Surgery, New York·Phase 2·NCT00674297·41 enrolled
Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
Terminated·AstraZeneca logoAstraZeneca·Phase 2·NCT02128269·9 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)